ERBB2 and neoplasm: Anti-HER1 panitumumab ADC possessing IR700 with a DAR of approximately 3 did not demonstrate tumor shrinkage after NIR light irradiation in in vivo assay using a tumor-xenografted mouse model bearing a 3T3/HER2 (HER1-negative) tumor in its dorsum, but it demonstrated tumor shrinkage after NIR light irradiation in in vivo assay using a tumor-xenografted mouse model bearing an A431 (HER1-positive) tumor in its dorsum [101].